Candel Therapeutics Inc (CADL) - Total Assets
Based on the latest financial reports, Candel Therapeutics Inc (CADL) holds total assets worth $201.92 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Candel Therapeutics Inc cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Candel Therapeutics Inc - Total Assets Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See CADL net assets for net asset value and shareholders' equity analysis.
Candel Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Candel Therapeutics Inc's total assets of $201.92 Million consist of 95.6% current assets and 4.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 95.6% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Candel Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Candel Therapeutics Inc market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Candel Therapeutics Inc's current assets represent 95.6% of total assets in 2025, a decrease from 98.5% in 2019.
- Cash Position: Cash and equivalents constituted 95.6% of total assets in 2025, up from 11.3% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Candel Therapeutics Inc Competitors by Total Assets
Key competitors of Candel Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
|
China | CN¥8.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Sk Biopharmaceuticals Co Ltd
KO:326030
|
Korea | ₩1.20 Trillion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
TELIX Pharmaceuticals Ltd
AU:TLX
|
Australia | AU$1.19 Billion |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Theravance Biopharma Inc
F:0TB
|
Germany | €415.46 Million |
Candel Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 28.05 | 4.64 | 5.44 |
| Quick Ratio | 28.05 | 4.64 | 5.44 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $190.70 Million | $73.08 Million | $19.93 Million |
Candel Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Candel Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.33 |
| Latest Market Cap to Assets Ratio | 4.78 |
| Asset Growth Rate (YoY) | 17.2% |
| Total Assets | $125.19 Million |
| Market Capitalization | $597.89 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Candel Therapeutics Inc's assets at a significant premium (4.78x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Candel Therapeutics Inc's assets grew by 17.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Candel Therapeutics Inc (2019–2025)
The table below shows the annual total assets of Candel Therapeutics Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $125.19 Million | +17.15% |
| 2024-12-31 | $106.87 Million | +159.38% |
| 2023-12-31 | $41.20 Million | -47.53% |
| 2022-12-31 | $78.52 Million | -11.98% |
| 2021-12-31 | $89.20 Million | +133.02% |
| 2020-12-31 | $38.28 Million | -16.60% |
| 2019-12-31 | $45.90 Million | -- |
About Candel Therapeutics Inc
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of … Read more